ACE2 and COVID-19: We speculated that the effects observed in COVID-19 patients treated with Thal or Len could likely be caused by a p63 degradation–dependent reduction of ACE2 levels, and that this downmodulation could reduce the SARS-CoV-2 viral infection and, in COVID-19 patients, viral re-entry.